Skip to main content

Together we are beating cancer

Donate now
  • Science & Technology

Cachexia: understanding why some people with cancer lose weight

by Sydney Ghazarian , Tim Gunn | Analysis

19 November 2026

0 comments 0 comments

Man wearing black socks and grey joggers on a glass digital scale with 116.6 kg displayed

Cachexia doesn’t make headlines, but it can be one of the most difficult aspects of dealing with cancer.

It’s a complex, life-threatening syndrome that can affect nearly 8 in 10 people with late-stage cancer, as well as some people with other advance staged illnesses.

People with cachexia lose muscle and fat tissue, which causes severe weight loss (“wasting”) that can’t be reversed by eating or supplements. As it saps people’s strength, it makes treatment much more difficult.

Given its devastating effects, scientists have been trying to uncover the causes of cancer cachexia, so they can protect people with the highest risk. So far, they’ve struggled to find a clear answer.

But a recent study from Cancer Grand Challenges team CANCAN may have opened a new way forward. The team’s unique approach is helping untangle the condition’s complexities to identify new ways to prevent it in the future.

Putting down the textbook

Dr Ed Reznik is a computational biologist at Memorial Sloan Kettering Cancer Center (MSK) in New York. His lab develops computer models that look at how cancers get and use energy, which helps show which people will benefit from different types of cancer treatment.

He heard a talk from Dr Tobias Janowitz, one of the lead researchers in CANCAN, about how cachexia changes how people with cancer get and use energy and thought his skills could help.

Ed Reznik smiling in a brown collared t-shirt.

He learned that people with cancer cachexia don’t often survive as long and have a poor quality of life.

“It dawned on me one day,” Reznik says, “that maybe the reason that cancer patients with cachexia have inferior outcomes is because they’re too weak to receive their treatments.”

He felt like he had just uncovered something new, something that hadn’t been thought of before. But when he told his wife, a family doctor in the US (equivalent to a GP in the UK), her reaction suggested otherwise.

From her own practice, she’d seen how each patient’s circumstances, like the fatigue associated with cachexia, could impact their life and treatment.

As they talked, Reznik realised how big the gap can be between what his wife called his “textbook medicine” and her “day-to-day medicine” when it comes to cachexia.

The textbook view looks at cachexia like a singular, clearcut condition. It says that to have cachexia, people need to lose 5% of their body weight over six months.

But day-to-day, practical medicine also considers how cachexia actually affects people. Doctors see it as a condition that’s entangled with the other challenges their patients face –  something unique to each person’s experience, and much harder to define.

“Some people eat tons of food and lose weight, while others lose the desire to seek out food,” Reznik explains. “In other cases, they have obstructions in their GI tract and they can’t get nutrition. All these things can happen.”

This complexity can be obscured by textbook definitions. Reznik was about to find out how that was holding research back.

Focusing on patients

After joining CANCAN, Reznik and his team set out to unpick cachexia’s complexities. They analysed the medical records of over 52,000 patients at MSK, including body weights, cancer type, tumour biology, treatments and blood test results.

With metaphorical textbook in hand, they tried to group people with cachexia together, comparing the six-month snapshots of when they lost 5% of their body weight.

It didn’t reveal anything.

But that’s when things began to click together. Reznik realised he needed to find a way to match the textbook to the reality.

“It’s not like patients line up at the clinic and then their cachexia immediately develops,” he says. “Cachexia takes time to emerge.”

Although the team accounted for lots of different factors, they hadn’t thought about the full journeys of the people whose (anonymised) data they were studying.

“You can’t just split people by whether they do or don’t have cachexia at one point,” he says. It’s a condition that emerges over time. To understand it, researchers need to think a bit more like the doctors and nurses who see people repeatedly through their cancer treatment. Or, in Reznik’s researcher terms: “account for how long you followed people for.”

So, second time round, instead of looking at a single six-month period, the team tracked trends in patients’ weight across an average of four years, analysing nearly 1.7 million measurements. This time, a much clearer picture began to emerge.

A new understanding of cachexia

The new approach showed that almost half of the people in MSK’s database developed cachexia at some point during their care, some more than once.

It typically occurred in distinct episodes. Some happened when patients’ cancers were actively growing or when their treatment started to fail, which was expected. Others, however, were less predictable, which hadn’t been observed before.

People with stomach cancer and pancreatic cancer were most at risk, and were more likely to develop cachexia earlier. But the condition could affect people with any cancer type, and at different stages, which suggests that something deeper was going on.

“We realised that patients can have an episode of cachexia at any point – at the beginning or the end of care – and that it can co-occur with episodes of disease progression,” Reznik says.

“Once we could see all these episodes of cachexia at once, it really changed the way that we could analyse or ask questions about cachexia.”

As they lined up their data, the team found that, across cancer types, cachexia comes with a consistent pattern of changes in the blood, including some linked to anaemia, inflammation and changes in the liver. This points to the fact that the condition involves the whole body, rather than just the cancer itself, which could help researchers better understand and diagnose cachexia in future.

The team also accounted for some of the other realities of cachexia, like tumours in places that can prevent people from eating and digesting food. And as they honed their data down, they found that people’s risk of cachexia seemed to change according to the specific changes in their cancer cells’ DNA. This suggests that genetic mutations could help explain the fundamental causes of the condition.

For example, the study showed that a mutation in a gene commonly linked to many different cancers, called TP53, was linked to a higher risk of cachexia in multiple cancer types. Other gene changes were specifically connected with an increased risk of cachexia in people with lung and bowel cancer. Two changes that appear in some bowel cancers even seemed to have a protective effect and make cachexia less likely.

From cachexia to cachexias

The findings haven’t fully explained the reasons for cachexia. In an important sense, they’ve made the condition even more complicated.

With the different ways that cachexia can present, researchers have started to think of it as more than a single condition.

“Certainly us, and even people outside of CANCAN, believe that there are different subtypes of cachexia,” Reznik says.

As they uncover the different forms, the team are using what they’ve learned to develop models to predict cachexia in some people with bowel cancer and lung cancer. Using a person’s cancer stage, general health, body mass index (BMI) and the new information about tumour mutations, they’ve shown they can predict whether people have a higher risk of developing cachexia within one, two and three years.

The models need further testing before they can be used in the clinic, but Reznik says they could one day help doctors intervene before cachexia takes hold, including through trials testing potential treatments for different subtypes.

“These findings bring us closer to recognising who is at risk – an important step towards finding ways to treat and ultimately prevent cachexia,” says Dr David Scott, director of Cancer Grand Challenges.

That’s crucial, but it’s something else the team learned that may take them furthest. Now, they understand how to combine their textbook knowledge and computational skills with the practical challenges doctors face.

“I have maybe three or four physicians that come to our lab meeting every week,” Reznik says. “As computational scientists, we have our own ideas, and they steer us in directions that align with their clinical experience.”

As the team continue to refine their analyses, they’re working closely with doctors to keep the patients facing cachexia at the heart of their work.

Cancer Grand Challenges is a global initiative funded by Cancer Research UK and the National Cancer Institute in the US to identify and take on cancer’s greatest challenges. You can find out more about CANCAN and other teams it funds through their website. 

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.